COBAS HPV TEST
Roche Molecular Systems, Inc. · Decision date Apr 19, 2011
What did the FDA approve?
FDA approved the cobas HPV Test from Roche Molecular Systems, Inc. on April 19, 2011. The device is a qualitative in vitro PCR and nucleic acid hybridization test that detects 14 high-risk HPV types in one analysis, specifically identifying HPV 16 and HPV 18 while concurrently detecting types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.
The approved indications cover patients 21 years and older with ASC-US cervical cytology results to determine need for colposcopy referral and to assess presence or absence of HPV genotypes 16 and 18. In women 30 years and older, the test can be used adjunctively with cervical cytology to screen for high-risk HPV types, and to assess presence or absence of genotypes 16 and 18. The approval order contains additional statement detail not reproduced in the database entry.
FDA approval order statement
APPROVAL FOR THE COBAS HPV TEST. COBAS HPV TEST INDICATIONS FOR USE: THE COBAS HPV TEST IS A QUALITATIVE IN VITRO TEST FOR THE DETECTION OF HUMAN PAPILLOMAVIRUS (HPV) IN PATIENT SPECIMENS. THE TEST UTILIZES AMPLIFICATION OF TARGET DNA BY THE POLYMERASE CHAIN REACTION (PCR) AND NUCLEIC ACID HYBRIDIZATION FOR THE DETECTION OF 14 HIGH-RISK (HR) HPV TYPES IN A SINGLE ANALYSIS. THE TEST SPECIFICALLY IDENTIFIES TYPES HPV 16 AND HPV 18 WHILE CONCURRENTLY DETECTING THE REST OF THE REST OF THE HIGH RISK TYPES (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 AND 68). THE COBAS HPV TEST IS INDICATED: 1) TO SCREEN PATIENTS 21 YEARS AND OLDER WITH ASC-US (ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE) CERVICAL CYTOLOGY TEST RESULTS TO DETERMINE THE NEED FOR REFERRAL TO COLPOSCOPY; AND 2) TO BE USED IN PATIENTS 21 YEARS AND OLDER WITH ASC-US CERVICAL CYTOLOGY RESULTS, TO ASSESS THE PRESENCE OR ABSENCE OF HIGH-RISK HPV GENOTYPES 16 AND 18. THIS INFORMATION, TOGETHER WITH THE PHYSICIAN¿S ASSESSMENT OF CYTOLOGY HISTORY, OTHER RISK FACTORS, AND PROFESSIONAL GUIDELINES, MAY BE USED TO GUIDE PATIENT MANAGEMENT. THE RESULTS OF THIS TEST ARE NOT INTENDED TO PREVENT WOMEN FROM PROCEEDING TO COLPOSCOPY; 3) IN WOMEN 30 YEARS AND OLDER, THE COBAS HPV TEST CAN BE USED WITH CERVICAL CYTOLOGY TO ADJUNCTIVELY SCREEN TO ASSESS THE PRESENCE OR ABSENCE OF HIGH RISK HPV TYPES. THIS INFORMATION, TOGETHER WITH THE PHYSICIAN¿S ASSESSMENT OF CYTOLOGY HISTORY, OTHER RISK FACTORS, AND PROFESSIONAL GUIDELINES, MAY BE USED TO GUIDE PATIENT MANAGEMENT; AND 4) IN WOMEN 30 YEARS AND OLDER, THE COBAS HPV TEST CAN BE USED TO ASSESS THE PRESENCE OR ABSENCE OF HPV GENOTYPES 16 AND 18. THIS INFORMATION, TOGETHER WITH THE PHYSICIAN¿S ASSESSMENT OF CYTOLOGY HISTORY, OTHER RISK FACTORS, AND PROFESSIONAL GUIDELINES, MAY BE USED TO GUIDE PATIENT MANAGEMENT....(SEE APPROVAL ORDER FOR ADDITIONAL APPROVAL STATEMENT DETAIL).
- Regulatory pathway
- Original PMA
- Clinical specialty
- Microbiology
- Decision date
- Apr 19, 2011
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P100020
- Regulatory pathway
- Premarket approval application
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- MAQ
- Decision code
- APPR
- Decision date
- Apr 19, 2011
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- MAQ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P100020 received
Application receipt date recorded by FDA.
P100020 · FDA decision
APPR
P100020/S066 · Related supplement
cobas HPV
Timeline entries are records held by MedtechLedger for P100020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
cobas HPVP100020/S066 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Explore the linked device profile
Other records with product code MAQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
cobas HPVP190028/S026 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Alinity m HR HPVP230003/S019 | Abbott Molecular, Inc. | PMA supplement | Sep 2, 2026 | FDA |
Alinity m HR HPVP230003 | Abbott Molecular, Inc. | PMA approval | Nov 1, 2023 | FDA |
| Roche Molecular Systems, Inc. | PMA approval | Apr 3, 2020 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche Molecular Systems, Inc.
- Headquarters
- Not reported
- Brand website
- roche.com
- FDA applicant address
- 4300 Hacienda Dr., Pleasanton, CA, 94588
Sources and methodology
- Original FDA record: P100020
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



